Alere Inc. (NYSE: ALR), a global leader in rapid diagnostic tests, has provided an update on the decision by the Centers for Medicare & Medicaid Services (CMS) to revoke Arriva Medical’s Medicare billing privileges.
Arriva issued the following statement:
For more than seven years, Arriva has reliably and responsibly provided diabetes testing supplies to Medicare beneficiaries. Today, Arriva serves more than half of the participants in the CMS program. We believe the recent action by CMS to remove Arriva from CMS billing is unlawful, arbitrary and capricious, and harmful to the more than 500,000 patients who depend on Arriva for these critical supplies. Our commitment to patients is unwavering, and because we are confident that this ruling will be overturned, Arriva is continuing to provide patients with the supplies they need as the appeals process proceeds. We are confident that Arriva is in compliance with CMS guidelines and look forward to an expeditious and favorable outcome for both Arriva and the hundreds of thousands of patients who depend on us. The number of purported instances cited by CMS is de minimis relative to the nearly 5.8 million total claims filed by Arriva during that same period.